Antibody response to HPV16 E7 oncoprotein may represent a marker of cervical cancer. A HPV16 GST-E7 fusion protein was used in a Western Blot assay to analyse the HPV16 E7 antibody response in 30 patients before and after treatment for cervical carcinoma (stage IIB or IIIB). Patients were treated wi
Range of HPV 16 E7 antibodies in cervical cancer patients, and healthy subjects
✍ Scribed by Alena Suchánková; Martin Krčmář; Viktor Krchňák; Eva Hamšíková; Jir̂ar; Kaňka; Josef Vágner; Vladimír Vonka
- Publisher
- John Wiley and Sons
- Year
- 1992
- Tongue
- French
- Weight
- 170 KB
- Volume
- 51
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
High-risk human papillomaviruses (HPV), particularly HPV 16, are associated with invasive cervical cancer (ICC), and persistent high-risk HPV infection is considered to be a marker for progressive cervical intra-epithelial neoplasia (CIN). However, most high-risk, HPV-infected, pre-cancerous lesions
## Abstract The cellular tumor suppressor p16 is strongly overexpressed in cervical cancers and precancers. We have previously demonstrated that infiltrating T lymphocytes reactive against p16 can be found in cervical cancer patients. Here, we analyzed whether p16 induces humoral immune responses.
Persistent infection of the uterine cervix with high-risk human papillomaviruses (HPV) is causally associated with cancer of the cervix. A few studies have reported the presence of HPV DNA in the blood of women with cervical neoplasia. The aim of this study was to determine if HPV DNA could be detec
## Abstract We have tested the safety and feasibility of a synthetic long peptide‐based HPV16‐specific skin test to detect cellular immune responses to HPV16 E2, E6 and E7 __in vivo__. Women with cervical neoplasia (__n__ = 11) and healthy individuals (__n__ = 19) were intradermally challenged with
High rates of cervical cancer have been reported from parts of China and this may reflect a predominance of cervical infection with particularly aggressive human papillomavirus (HPV) variants. This PCR-based investigation of cervical tumours from Sichuan province in central China demonstrated an HPV